As the cannabis market has started to recover amidst the COVID-19 pandemic, investors are looking at where the market can grow.

One leading candidate is cannabinoid production. THC, CBD, and other specific cannabinoids can be useful for a variety of treatments, including for pain, anxiety, obesity, and other significant indications. With the health and wellness sector of cannabis slated to grow, the manufacturing of targeted, 100% pure cannabinoids can lead to profitability.

Some of the highest quality cannabinoids in the business come from Canadian-based Willow Biosciences Inc. (TSX:WLLW, OTC:CANSF, Forum). The biotechnology company has been using biosynthesis to develop pharmaceutical-grade, plant-derived cannabinoids for a variety of markets, and they've had a busy 2020 with impressive steps taken in CBD production and partnerships secured with development partners.

Now, with the CBD market continuing to open up, Willow Biosciences is on track for commercialization six months ahead of schedule. What does that road-map look like, and how does biosynthesis get the Company there? CEO Trevor Peters joined Omri Wallach of Stockhouse Media remotely to discuss the technology advantage of Willow Biosciences and the evolving CBD market.